Waddah Arafat, MD, discusses how the use of neoadjuvant chemotherapy in MIBC has changed relative to the addition of immunotherapy to this paradigm.
Waddah Arafat, MD
Advertisement
Waddah Arafat, MD, is an associate professor of internal medicine and a member of the Division of Hematology and Oncology at the University of Texas (UT) Southwestern Medical Center; as well as medical director of the Clinical Cancer Informatics Program at the UT Southwestern Harold C. Simmons Comprehensive Cancer Center
Articles by Waddah Arafat, MD
Advertisement
Latest Updated Articles
Dr Arafat on Evolving Neoadjuvant Treatment Strategies in MIBCPublished: August 29th 2025 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
5